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15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an electrophilic lipid mediator derived 
from PGD2 with potent anti-inflammatory effects. These are likely to be due to the cova-
lent modification of cellular proteins, via a reactive α,β-unsaturated carbonyl group in 
its cyclopentenone ring. This study was carried out to identify novel cellular target(s) 
for covalent modification by 15d-PGJ2 and to investigate the anti-inflammatory effects 
of the prostaglandin on endothelial cells (EC). The data presented here show that 15d-
PGJ2 modifies and inhibits components of the proteasome and consequently inhibits 
the activation of the NF-κB pathway in response to TNF-α. This, in turn, inhibits the 
adhesion and migration of monocytes toward activated EC, by reducing the expression 
of adhesion molecules and chemokines in the EC. The effects are consistent with the 
covalent modification of 13 proteins in the 19S particle of the proteasome identified by 
mass spectrometry and the suppression of proteasome function, and were similar to 
the effects seen with a known proteasome inhibitor (MG132). The ubiquitin–proteasome 
system has been implicated in the regulation of several inflammatory processes and the 
observation that 15d-PGJ2 profoundly affects the proteasome functions in human EC 
suggests that 15d-PGJ2 may regulate the progression of inflammatory disorders such 
as atherosclerosis.
Keywords: 15d-PgJ2, proteasome, covalent modification, inflammation, adhesion molecules, chemokines, 
monocyte adhesion, atherosclerosis
inTrODUcTiOn
Prostaglandins are a family of related compounds derived from arachidonic acid that are released 
from cell membrane stores in response to a range of stimuli including cytokines (1). One of these 
products, PGD2, is an abundant prostaglandin in several tissues. PGD2 activates G-protein-coupled 
receptors on its target cells, but PGD2 also undergoes dehydration in vivo and in vitro to generate 
cyclopentenone metabolites of the J series, including 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) 
(2, 3). 15d-PGJ2 represses inflammatory responses in several models, including modulation of genes 
such as iNOS, TNF-α, and COX-2 (4, 5). 15d-PGJ2 was also identified as a potent ligand of the 
nuclear receptor, PPAR-γ (6–8). There is evidence that at least some of these anti-inflammatory 
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effects are mediated through the covalent modification of cellular 
proteins, via its reactive α,β-unsaturated carbonyl group (9–15), 
which in turn modifies their biological functions (14).
One key target of 15d-PGJ2 is the NF-κB pathway comprising 
a cluster of proteins that regulate the inflammatory responses 
in cells. The NF-κB family consists of RelA (p65), NF-κB1 
(p50/p105), NF-κB2 (p52/p100), c-Rel, and RelB. The p50 and 
p52 subunits are derived on proteolytic cleavage of precursors 
p105 and p100, respectively, by the proteasome. The binding of 
Rel proteins to p50 and p52 forms dimeric complexes that in 
turn bind DNA to regulate the transcription of many inflam-
matory genes, including cytokines, chemokines, and adhesion 
molecules, as well as antiapoptotic and antioxidant genes. In 
many cell types, the most abundant form of NF-κB is the p50/
p65 heterodimer, which binds to a responsive element found in 
the promoter of several atherogenic genes, including adhesion 
molecules and chemokines which, in turn, regulate monocyte 
recruitment (16). The NF-κB heterodimer remains in an inactive 
form in the cytoplasm, forming a complex with the inhibitory 
protein of NF-κB, the IκBs. Potent NF-κB activators, such as 
TNF-α, cause almost complete degradation of IkBs (especially 
IkB-α) within minutes. This process is mediated by the 26S 
proteasome and depends on phosphorylation of IkBs. The 
control of IkB phosphorylation is mediated by IkB kinase (IKK) 
complex. 15d-PGJ2 inhibits IKK, thus preventing IkB degrada-
tion and NF-κB nuclear translocation (17). It can also directly 
modify NF-κB subunits blocking their ability to bind DNA (18). 
Activation of the NF-κB pathway is further dependent on the 
function of the ubiquitin–proteasome system (UPS), which 
is a key regulator of the protein turnover and degradation in 
human cells. Inflammatory cell signaling promotes the dissocia-
tion of IκB-α from NF-κB and is processed by the proteasome. 
Inflammatory cell signaling also promotes the processing of the 
p105 precursor by the proteasome, to generate mature P50 subu-
nits. If the proteasome is inhibited, degradation of both IκB-α 
and p105 is prevented and they remain complexed to NF-κB 
heterodimer preventing its activation (19).
The 26S proteasome is a large proteolytic complex that 
regulates a variety of important physiologic and pathologic 
cellular processes by selective degradation of proteins (20). The 
26S complex consists of two asymmetric 19S caps linked to a 
barrel-shaped core, the 20S proteasome. During the process of 
degradation, a polyubiquitinated protein is first recognized by 
the 19S regulatory particle, unfolding the protein and translocat-
ing it to the 20S core particle where it is subjected to various types 
of protease activity (21). The UPS regulates cellular processes and 
pathways implicated in the development of many diseases. For 
example, proteolysis and protein turnover in the brain are key 
processes in the formation of protein deposits in neurodegenera-
tive disease (22). Also in cancer, UPS has been shown to control 
the abundance and activity of oncogenes and to promote tumo-
rigenesis directly by the degradation of tumor suppressor p53 
(23). Thus, proteasome inhibitors are currently used in cancer 
therapy (24).
Other inflammatory diseases have been shown to involve UPS, 
including atherosclerosis (25), in which the proteasome activity 
has been linked to foam cell formation, and to the smooth muscle 
cell transformation, proliferation, and migration that are charac-
teristics of atherosclerotic plaque (26). In the current work, we 
explored whether inhibition of proteasomal activity occurred as 
a consequence of covalent modification of its component proteins 
by 15d-PGJ2, and the effect of 15d-PGJ2 on UPS activity, and the 
inflammatory responses, of human endothelial cells (EC).
MaTerials anD MeThODs
antibodies
NF-κB p65, p50, and p105 subunits antibodies and Ik-β and anti-
rabbit secondary antibody were obtained from Cell Signaling 
Technology (MA, USA). The β-actin, anti-ubiquitin, anti-biotin, 
PSMD2, PSMD3, PSMD11, 20S Proteasome β1, 20S Proteasome 
α1, polyclonal anti-mouse secondary antibodies, and Protein 
A/G plus agarose beads were from Santa Cruz Biotechnology 
(CA, USA). Anti-PSMD1 and anti-TBP antibodies were from 
Sigma-Aldrich (Dorset, UK).
cell culture and Prostaglandin Treatments
Human aortic endothelial cells were obtained from Cascade 
Biologics – Invitrogen cell culture (Carlsbad, CA, USA) and were 
grown in EC culture media MV plus growth supplements from 
Promo Cell (Heidelberg, DE, USA) supplemented with 100 units/
ml penicillin and 100 μg/ml streptomycin. For experiments, 80% 
confluent ECs were incubated in EC basal media from Promo 
Cell (2% fetal calf serum, 0.4% EC growth supplements, 90 μg/ml 
heparin and with 100 U/ml penicillin, and 100 μg/ml streptomy-
cin) for 24 h before treatments. THP-1 monocytes were purchased 
from the LGC Promochem (Middlesex, UK) and were maintained 
in RPMI 1640 media supplemented with 10% fetal bovine serum, 
1% l-glut, and 1% P/S. The cells were passaged twice weekly in 
complete media at a ratio of 1:5. All cell lines were maintained in 
an incubator at 37°C and 5% CO2. For cell counts and viability 
determination, the cells were diluted 1:1 with trypan blue and 
counted using a hemocytometer. 15-Deoxy-Δ12,14-prostaglandin 
J2, biotin-15-deoxy-Δ12,14-prostaglandin J2, prostaglandin D2, and 
biotin-prostaglandin D2 were purchased from Cayman Chemical 
(Ann Arbor, MI, USA). To change the solvent for experiments, 
prostaglandins were dried down and re-suspended in ethanol at 
a concentration of 1 mg/ml. For experiments, ethanol was used 
as vehicle control.
immunoprecipitation
Endothelial cells were treated with prostaglandins for 4  h at 
37°C. After incubation, the EC were solubilized in lysis buffer 
(1% Non-idet P-40, 0.1% SDS, 150 mM NaCl, 50 mM Tris–HCl, 
pH 7.2) and complete protease inhibitor (Roche Diagnostics, 
Germany). Immunoprecipitation of human plaques proteins was 
carried out by solubilizing the tissues in T-PER Tissue Protein 
Extraction Reagent (Thermo Scientific, IL, USA) and complete 
protease inhibitor (Roche Diagnostics, Germany) and subsequent 
homogenization in a tissue lyser. The samples were centrifuged 
(12,000 × g for 10 min at 4°C) and 300 μg of total cell extract 
was diluted to 500 μl with lysis buffer. The sample was incubated 
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in 2 μg of antibody at 4°C for 2 h and 25 μl of Protein A/G plus 
agarose beads added to the sample prior to incubation overnight 
at 4°C. The immunoprecipitates were washed four times with lysis 
buffer and proteins were eluted with SDS sample buffer (63 mM 
Tris–HCl, 10% glycerol, 2% SDS, 0.0025% bromophenol blue, 
pH 6.8) and analyzed by SDS-PAGE, followed by Western blot-
ting. Antibodies to PSMD2, PSMD3, PSMD11, 20S Proteasome 
α1, and 20S Proteasome β1 were obtained from Santa Cruz 
Biotechnology (CA, USA) and used for immunoprecipitation 
experiments.
sDs-Page and Western Blotting
Protein samples of interest were run on 4–20% polyacryla-
mide gels and subjected to electrophoresis. The gels were 
electrophoresed in Tris–HEPES running buffer (0.1M Tris, 
0.1M HEPES, 3  mM SDS, pH 8) using a Mini-PROTEAN 3 
Electrophoresis System (Biorad) at 80 V for 15 min and 120 V 
for the duration of the run. SDS-PAGE separated proteins 
were transferred to nitrocellulose membrane in transfer buffer 
(25 mM Tris, 192 mM glycine, 20% v/v MeOH). Transfer was 
carried out for 90 min at 80 V on ice. The membranes were stained 
with the reversible stain Ponceau-S solution to check transfer 
efficiency and destained in distilled water. The membranes ware 
then blocked for 2  h in 5% BSA in TBS-T (20  mm Tris, pH 
7.6, 150  mm NaCl, 0.1% Tween 20) at room temperature on 
an orbital shaker. The membranes were subsequently incubated 
with the appropriate dilution of primary antibody overnight. 
Following incubation, the membranes were washed three 
times in TBS-T and incubated with the appropriate dilution 
of secondary antibody for 1.5 h. After three washes in TBS-T 
for 15 min, the membranes were developed using Supersignal 
enhanced Chemiluminesence reagents (Thermo Scientific, IL, 
USA) and exposed to photographic X-ray film.
Bioinformatic analysis
The 358 proteins covalently modified by 15d-PGJ2, in EC (27), 
were subjected to pathway mapping analysis and were distributed 
into categories according to their cellular component, molecular 
function, and biological process using Gene Ontology (GO), a 
web-based platform available for interpreting set of GO hierar-
chies and the PANTHER classification system.1 The identified 
proteins were subjected to pathway mapping analysis using the 
KEGG pathway database (DAVID Bioinformatics Resources 6.7). 
To filter the results, a threshold of two proteins per pathway and a 
significance level of p < 0.01 were applied.
MTT assay for cell Viability
The cell viability of EC treated with 15d-PGJ2 or MG132 was 
evaluated by MMT assay. The following dose–response was 
applied for 15d-PGJ2: 0, 1, 5, 10, and 25 μM. The cell viability after 
treatment with MG132 was assayed at 100  nM (the dose used 
for experiments). After 18 h of treatment, 5 mg/ml of dimeth-
ylthiazol-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, 
1 www.pantherdb.org. 
Ireland) solution was added to EC and incubated at 37°C, 5%CO2 
for 3.5 h. Following cell lysis with DMSO, absorbance was spec-
trophotometrically read at 570 nm. For experiments, 15d-PGJ2 
doses which did not significantly reduce cell viability were chosen 
(97.2 ± 4% viability with 1 μM 15d-PGJ2, 95.4 ± 4% with 5 μM, 
and 90.5 ± 6% with 10 μM), while EC viability was significantly 
decreased at 72.7 ± 8% with 25 μM 15d-PGJ2. EC viability treated 
with 100 nM MG132 was 93.5 ± 4%.
Proteasome activity assay
Lysates of EC treated with 15d-PGJ2 or MG132 for 18  h were 
used to measure the chymotrypsin-like activity of the protea-
some using the peptide substrate SUC-LLVY-AMC and 50 μg 
of proteins per assay. A commercially available kit (Cayman 
Chemical, Ann Arbor, MI, USA) was used to perform the assay 
according to the manufacturers’ guidelines. AMC hydrolysis was 
measure in a Spectramax M2 (Molecular Devices, CA, USA) 
plate fluorescence reader with 360-nm excitation and 460-nm 
emission wavelength. The proteasome inhibitor epigallocatechin 
gallate (EGCG) was used as control to demonstrate specificity 
of the substrate in this assay. The experiments were repeated in 
triplicate.
19s Proteasome-15d-PgJ2-Binding assay
A high-binding polystyrene microplate (R&D, MN, USA) was 
coated overnight at 4°C with 40 μg/ml of purified 19S Proteasome 
(Boston Biochem, MA, USA) in PBS. After incubation, the plate 
was washed four times with 0.05% Tween 20 in PBS and 100 μl 
solution of biotinylated-15d-PGJ2 or biotinylated-15d-PGD2 in 
PBS was added to the wells and incubated for 2  h at RT with 
gentle shaking. A binding competition assay was performed to 
determine the binding specificity of biotinylated-15d-PGJ2 to 
the proteasome proteins. Specifically, the 19S-coated plate was 
pre-incubated with 10- and 20-fold molar excess of 15d-PGJ2 
for 2 h at RT and subsequently with biotinylated-15d-PGJ2 for 
a further 2 h at RT. After incubation, the plate was washed four 
times with 0.05% Tween 20 in PBS. After washing, a blocking 
solution of 4% BSA in PBS was subsequently added for 2 h at 
RT with gentle shaking. Subsequently, a solution of 1:750 (v:v) 
streptavidin–horseradish peroxidase conjugate (GE Healthcare, 
USA) was incubated for 1 h at RT. After washing four times with 
0.05% Tween 20 in PBS, 100  μl of substrate reagent solution 
(R&D, MN, USA) was incubated for 30 min at RT with gentle 
shaking. The reaction was stopped with 25  μl of 2M sulfuric 
acid, and the absorbance was read at 450  nm with correction 
at 540 nm in a Spectramax M2 (Molecular Devices, CA, USA) 
plate reader.
immunocytochemistry
Endothelial cells were grown on cover slips for fluorescence 
microscopy and treated with 15d-PGJ2 or MG132 for 18 h and 
subsequently stimulated with 0.2 ng/ml TNF-α for 30 min. The 
cells were fixed with formaldehyde (3%) for 15  min followed 
by blocking in 5%BSA in PBS for 1 h. EC were then incubated 
with the appropriate dilution of primary antibody followed by 
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incubation with fluorescent secondary antibody (Alexa Fluor 
488, Invitrogen). Subsequently, the cells were stained with Alexa 
Fluor 568-phalloidin to stain actin microfilaments and with DAPI 
to visualize nucleic acid. The stained cells were analyzed by using 
a Zeiss AxioImager M1 fluorescent microscope, and the images 
were captured using an Olympus digital camera (Optronics, 
Goleta, CA, USA). Pictures were processed using AxioVision 
software.
adhesion assay
For static adhesion assay, 4 ×  104 EC were seeded in a 96-well 
plate for 24 h and then treated with 15d-PGJ2 or MG132, for 18 h. 
Subsequently, EC were stimulated with TNF-α (0.2 ng/ml) for 6 h. 
After treatments, the wells were washed three times with medium, 
and 1 × 105 fluorescein-labeled THP-1 monocytes were added to 
each well and incubated for 30 min at 37°C. After incubation, the 
wells were washed three times with fresh medium and adher-
ent monocytes were measured in a Spectramax M2 (Molecular 
Devices, CA, USA) plate fluorescence reader with 485-nm excita-
tion and 530-nm emission wavelength. For photomicrographs, 
fluorescence-labeled adherent monocytes in the 96-well plate were 
analyzed using a Zeiss AxioImager M1 fluorescent microscope. 
Adhesion assay experiments were repeated in triplicate, and the 
average value was expressed as a percentage of vehicle control.
Migration assay
THP-1 monocytes were applied to 24-well transwell migration 
plates (Invitrogen, USA), consisting of upper and lower cham-
bers, separated by membranes punctuated with pores of 5 μm in 
diameter. The 1 × 105 monocytes were seeded in a final volume 
of 150-μl basal medium into the upper chamber. Conditioned 
medium was prepared from confluent EC treated with 15d-PGJ2 
or MG132 for 18 h; the cells were washed, fresh medium was 
added, and then the cells were treated with TNF- α (0.2 ng/ml 
for 6  h). After incubation, conditioned medium was cleared 
by centrifugation (14,000 × g for 10 min at 4°C). Conditioned 
medium was added to the lower chamber in a final volume of 
500 μl as a chemoattractant. Plates were incubated for 2  h at 
37°C. Membranes were washed with PBS and were placed into 
4% formaldehyde for 15 min to fix cells adherent to the under-
side of the membrane. Membranes were washed with PBS, and 
the upper chambers immersed in DAPI solution for 3 min, for 
nucleic acid staining. Following two PBS washes, the adherent 
cells were visualized using a Zeiss AxioImager M1 fluorescent 
microscope. The number of cells in five random 20× fields was 
counted, and the average value was expressed as a percentage of 
control.
Flow cytometry
Following 15d-PGJ2 or MG132 treatments (18 h) and activation 
with TNF- α (0.2 ng/ml for 6 h), the EC were harvested to be stained 
for flow cytometric analysis. To block non-specific binding, EC 
were incubated in 2% BSA in PBS (blocking buffer) for 15 min 
before adding the antibodies. FITC-VCAM-1, PE-ICAM-1, 
and APC-E-selectin antibodies (BD, Rankling Lakes, NJ, USA) 
were used to label EC in 2% BSA in PBS. The antibodies were 
incubated for 30 min at room temperature. Following two washes 
with blocking buffer, the cells were fixed in 2% paraformalde-
hyde. Forward and side scatter gates were established to exclude 
non-viable cells and cell debris from the analysis. The mean 
fluorescence intensity of 2 × 105 cells was analyzed in each sample. 
Auto-fluorescence signals generated by unlabeled cells were used 
as negative controls in each experiment. Flow cytometric analysis 
was performed on an Accuri C6 instrument and analyzed with 
CFlow® Software (Accuri, Ann Arbor, MI, USA). The data were 
expressed as median fluorescence intensity of three independent 
experiments.
statistical analysis
The data were analyzed by parametric unpaired Student’s t-test 
and analysis of variance (ANOVA). The Student’s t-test was 
used to compare the mean of two data sets. ANOVA was used 
to examine any overall differences between treatments groups. 
Results were expressed as mean ±  SEM. Experimental points 
were performed in triplicate with a minimum of three independ-
ent experiments. A value of p < 0.05 was considered statistically 
significant.
resUlTs
The Proteasome complex is a Target of 
15d-PgJ2
In our previous work (27), conjugation targets of 15d-PGJ2 were 
identified by a chemical proteomic approach where human EC 
were exposed to 5 μM 15d-PGJ2 that had been biotinylated at 
the carboxyl group, leaving the reactive cyclopentenone ring 
unmodified. A total of 358 proteins complexing with 15d-PGJ2 
were identified by affinity purification and subsequent liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) 
(27). The MS data are available in PRIDE proteomics iden-
tification database2 under accession numbers 27957–27962. 
Functional annotations were available for 355 of the 358 pro-
teins identified. The analysis showed the proteasome complex 
to be disproportionally represented (fold enrichment =  8.30, 
p = 2.20E−08) with 13 proteins in this pathway identified in 
our dataset. The identified proteasome proteins, together with 
the corresponding MS identification details, are detailed in 
Table  1. Validation of several 15d-PGJ2 targeted proteasome 
proteins (Rpn1, Rpn2, Rpn3, and Rpn6) was performed by 
immunoprecipitation from EC treated with 5  μM biotin-
15d-PGJ2 and subsequent anti-biotin Western blot. As shown in 
Figures 1B,C, only the 19S proteasome proteins were modified 
by biotin-15d-PGJ2, while proteins in the 20S proteasome (α1 
and β1) were not modified. These results show an extraordinary 
level of specificity for the interaction of the proteasome with 
15d-PGJ2.
2 www.ebi.ac.uk/pride. 
TaBle 1 | list and details of proteasome proteins identified by liquid chromatography–tandem mass spectrometry (lc–Ms/Ms).
UniProt iD Protein identification MascOT score sequence coverage pi Peptide hits
PSMD2 26S proteasome non-ATPase regulatory subunit RPN1 107 39.4 5.08 21
PSD12 26S proteasome non-ATPase regulatory subunit RPN5 94 39.3 7.53 21
PSD11 26S proteasome non-ATPase regulatory subunit RPN6 94 55.7 6.08 19
PRS8 26S protease regulatory subunit RPT6 87 45.6 7.11 18
PRS6B 26S protease regulatory subunit RPT3 72 41.6 5.09 8
PSD7 26S proteasome non-ATPase regulatory subunit RPN8 71 22.2 6.29 5
PRS6A 26S protease regulatory subunit RPT5 70 30.3 5.13 13
PSMD6 26S proteasome non-ATPase regulatory subunit RPN7 65 40.1 5.45 14
PSMD3 26S proteasome non-ATPase regulatory subunit RPN3 53 32.2 8.47 13
PSD13 26S proteasome non-ATPase regulatory subunit RPN9 50 27.9 5.53 9
PSDE 26S proteasome non-ATPase regulatory subunit RPN11 49 35.5 6.06 7
PSMD1 26S proteasome non-ATPase regulatory subunit RPN2 43 33.1 5.25 24
PRS10 26S protease regulatory subunit RPT4 42 24.4 7.1 7
Biotin-15d-PGJ2-modified proteins from EC treated with 5 μM biotin-15d-PGJ2 were purified by affinity precipitation using neutravidin beads, separated by SDS-PAGE, and identified 
by LC–MS/MS.
5
Marcone et al. Proteasome Inhibition and Anti-inflammatory Effects of 15d-PGJ2
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 459
15d-PgJ2 covalently Binds to 19s 
Proteasome Proteins, inhibits Proteasome 
activity, and induces accumulation of 
Proteins conjugated to Ubiquitin
To further examine the covalent modification of 19S protea-
some proteins by 15d-PGJ2, an immunoplate was coated with 
purified 19S particle of the 26S proteasome and incubated 
in vitro with biotin-15d-PGJ2. Biotin labeling of 19S proteasome 
was observed at nanomolar concentration of biotin-15d-PGJ2 
(Figure 2A) demonstrating direct interaction of 15d-PGJ2 and 
proteasome proteins at low levels of the prostaglandin. The 
specificity of the interaction was confirmed by pre-incubating 
the coated plate with 10- and 20-fold molar excess of unlabeled 
15d-PGJ2, which prevented the binding of biotinylated pros-
taglandin, and by incubating 10 μM biotin-15d-PGJ2 with an 
irrelevant protein, BSA. In addition, biotin-PGD2 showed no 
binding, confirming the specificity of the interaction between 
15d-PGJ2 and the 19S. In our previous work, we demonstrated 
that covalent modification by 15d-PGJ2 profoundly altered the 
biological function of several proteins (14). Here, we explored 
the effect of 15d-PGJ2 covalent modification of proteasome 
components on proteasome catalytic activity and assayed in 
lysates of EC pretreated with the prostaglandin. The effects 
were compared to that of MG132, a well-known synthetic 
proteasome inhibitor which acts by covalently binding to the 
beta subunits of the proteasome (28). The proteolytic activity 
of the proteasome was assayed using a fluorogenic substrate 
(SUC-LLVY-AMC) (Figure  2B). The treatment with 15d-
PGJ2 inhibited the proteasome activity by 16 ±  2% at 1 μM, 
36 ±  4% at 5  μM, and 44 ±  7% at 10  μM compared to the 
vehicle control. For comparison, 100-nM MG132 decreased 
the proteasome activity by 58 ±  1%. The proteasome system 
degrades proteins that have been targeted for proteolysis by 
the addition of ubiquitin molecules. As shown in Figure 2C, 
anti-ubiquitin Western blot analysis of EC treated with 10-μM 
15d-PGJ2 or with 100-nM MG132 resulted in accumulation of 
proteins conjugated to ubiquitin, consistent with a decreased 
proteasomal activity.
effects of 15d-PgJ2 on cell signal-induced 
Degradation of iκB-α and p105 and on 
nF-κB nuclear Translocation
The proteasome system plays a critical role in the regulation of 
the inflammatory process in part by modulating the activation 
of the NF-κB pathway. In particular, the proteasome regulates 
two crucial steps of NF-κB activation, IκB-α degradation, and 
p105 processing, leading to the formation of active p50/p65 
dimers. If proteasome activity is inhibited by 15d-PGJ2, then 
degradation of both IkB-α and p105 would be prevented, and 
consequently, NF-κB pathway activation would be suppressed. 
As shown in Figures 3A,B, treatment of EC with increasing 
concentrations of 15d-PGJ2 (1–10 μM) or with the proteasome 
inhibitor MG132 prevented the proteolysis of IκB-α and p105 
induced by TNF-α. It should be noted however that 15d-PGJ2 
inhibits a number of other components of the NF-κB signal-
ing pathway resulting in the accumulation of IκB-α, including 
IKK and the p50 subunit, the latter by direct covalent modi-
fication (19).
In addition, NF-κB is normally held in an inactive state in 
the cytoplasm through interactions with IκB-α. TNF-α induces 
IκB-α degradation, freeing NF-κB to translocate to the nucleus 
and initiate transcription of proinflammatory genes. The nuclear 
localization of active NF-κB was detected by immunofluorescence 
experiments using a fluorescein isothiocyanate (FITC)-conjugated 
p65 antibody (Figure 3C). While in resting EC, p65 showed strong 
staining in an exclusively cytoplasmic localization, p65 was pre-
dominantly localized to the nucleus in the presence of TNF-α. In 
contrast, in the presence of 15d-PGJ2 and MG132, nuclear translo-
cation of p65 induced by TNF-α was reduced. These findings were 
confirmed by Western blotting of nuclear fractions obtained from 
TNF-α-activated EC, which showed that 15d-PGJ2 inhibited the 
nuclear localization of p65 and p50 induced by TNF-α, as did the 
synthetic proteasome inhibitor, MG132 (Figures 3D,E). In sum-
mary, in TNF-α-activated EC, treatment with 15d-PGJ2 resulted 
in the inhibition of the NF-κB pathway activation, by modulating 
the processing the NF-κB inhibitors, similarly to the effects of the 
proteasome inhibitor MG132.
FigUre 1 | The proteasome complex is a target of 15d-PgJ2. (a) (i) Structure of 15d-PGJ2 and (ii) mechanism of covalent modification of thiol-containing 
proteins by 15d-PGJ2 via S-conjugate addition. (B) EC were incubated with 5 μM biotin-15d-PGJ2 and biotin-15d-PGJ2 modified proteins were bound to neutravidin 
beads, analyzed by SDS-PAGE, and identified by LC–MS/MS (27). The red shapes in the schematic representation indicate the 13 proteins in the 19S regulatory 
particle modified by 15d-PGJ2. (c) Validation of MS results by Western blotting. EC were treated with or without 5-μM biotin-15d-PGJ2, and the proteasome 
proteins were affinity-precipitated using anti Rpn1, Rpn2, Rpn3, and Rpn6 antibodies. Modification by biotin-15d-PGJ2 was demonstrated by anti-biotin Western 
blot. Total cell lysates were used as positive controls (Control) for each antibody. Anti-20S proteasome antibodies (α1 and β1) were used to show the localization of 
the 15d-PGJ2 modification to the 19S regulatory subunits of the 26S proteasome.
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effect of 15d-PgJ2 on adhesion Molecule 
mrna and Protein expression in ec
Inhibition of the nuclear translocation of p65 and p50 by 15d-
PGJ2 would be expected to suppress the expression of NF-κB 
target genes induced in response to TNF-α, including adhesion 
molecules and chemokines. The effect of 15d-PGJ2 on TNF-α-
induced expression of adhesion molecules was determined in 
EC activated by TNF-α for 6  h (Figure  4A). TNF-α markedly 
FigUre 2 | 15d-PgJ2 covalently binds to 19s proteasome proteins, inhibits proteasome activity, and induces accumulation of proteins conjugated to 
ubiquitin. (a) The interaction of biotin-15d-PGJ2 with purified 19S proteasome was assayed on a 19S-coated ELISA plate. The specificity of the interaction was 
confirmed in competition assays using 10- and 20-fold molar excess of unlabeled 15d-PGJ2, and by using biotin-PGD2. Data are expressed as mean ± SEM vs. 
control of three independent experiments. ***p < 0.001, **p < 0.01, and *p < 0.05 biotin-15d-PGJ2 vs. vehicle (0 μM biotin-15d-PGJ2). $(p < 0.05) 10-fold molar 
excess of unlabeled 15d-PGJ2 vs. biotin-15d-PGJ2; ##(p < 0.01) 20-fold molar excess of unlabeled 15d-PGJ2 vs. biotin-15d-PGJ2; &&(p < 0.01) biotin-15d-PGJ2 in 
the absence of 19S proteasome. (B) The peptidase activity of the proteasome in EC lysates treated with 15d-PGJ2 for 18 h was measured using a fluorogenic 
substrate (SUC-LLVY-AMC). For comparison, the effect of the known proteasome inhibitor MG132 is shown. Inhibition of proteasome activity was expressed as 
fluorescence unit per wavelength and reported as percentage of control (ethanol) (mean ± SEM, n = 3); ***p < 0.001, **p < 0.01, and *p < 0.05 15d-PGJ2 or 
MG132 vs. vehicle. (c) Anti-ubiquitin Western blot analysis of EC treated with 10 μM 15d-PGJ2 or with 100-nM MG132 for 18 h resulted in accumulation of proteins 
conjugated to ubiquitin, consistent with a decreased proteasomal activity.
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increased mRNA expression of VCAM-1, ICAM-1, and E-selectin 
compared to vehicle control (p < 0.001). Pretreatment with either 
15d-PGJ2 or MG132 significantly suppressed the expression of 
mRNA for VCAM-1, ICAM-1, and E-selectin. These results 
were confirmed by flow cytometry (Figure 4B), which showed 
a dose-dependent decrease of EC surface protein expression of 
VCAM-1, ICAM-1, and E-selectin.
effect of 15d-PgJ2 on human Monocyte 
adhesion to activated endothelial cells
The induction of ICAM-1, VCAM-1, and E-selectin, among oth-
ers, facilitates the rolling and firm adhesion of monocytes to the EC 
surface of the vessel wall, a key process in vascular inflammation. 
Having confirmed the ability of 15d-PGJ2 to reduce adhesion mol-
ecule expression in EC treated with TFN-α, further experiments 
were undertaken to examine the effect of 15d-PGJ2 on monocyte 
adhesion to TFN-α-treated EC. As shown in Figures 5A,B, TNF-α 
caused a significant increase in the adhesion of human monocytes 
compare to vehicle (~19-fold, p < 0.001). Pretreatment with 15d-
PGJ2 inhibited the adhesion of monocytes on TNF-α-activated EC 
(by 11 ± 6, 89 ± 2, and 87 ± 4% with 1, 5, and 10 μM 15d-PGJ2, 
respectively). Similarly, MG132 decreased adhesion of monocytes 
by 90 1%, consistent with a role for the proteasome in regulating 
the pathways leading to monocyte adhesion.
FigUre 3 | effects of 15d-PgJ2 on cell signal-induced degradation of iκB-α and p105 and on nF-κB nuclear translocation. (a) EC were treated with 
15d-PGJ2 (1–10 μM) or MG132 (100 nM) for 18 h, followed by 30min stimulation with TNF-α (0.2 ng/ml). Proteasomal IkB-α degradation and p105 processing were 
estimated by Western blotting of the indicated protein, and β-actin was used as loading control. The effect of the proteasome inhibitor MG132 is also shown. The 
data for three independent experiments are shown. (B) Protein levels (assessed as ratio of protein OD normalized to the OD of β-actin) are shown as percentage of 
control (vehicle + TNF-α). Data are expressed as mean ± SEM of three independent experiments. $$(p < 0.01) vehicle vs. TNF-α; **p < 0.01 and *p < 0.05 15d-PGJ2 
or MG132 vs. TNF-α. (c) Epifluorescence microscopy was performed on EC treated with 15d-PGJ2 (1–10 μM) or MG132 (100 nM) for 18 h prior to activation with 
TNF-α (0.2 ng/ml) for 30 min at 20× (top panel) and 63× (bottom panel) magnification. DNA was stained with DAPI dye (blue), and NF-κB was stained with an anti 
p65 antibody and Alexa-488 conjugated secondary antibody (green). Images are representative of three independent experiments. (D) Western blot analysis of p65 
and p50 levels evaluated in nuclear extracts of TNF-α-activated EC pre-incubated with or without 15d-PGJ2 or MG132 (100 nM). An anti-TATA-binding protein (TBP) 
was used as loading control for EC nuclear fractions. (e) Protein levels (assessed as ratio of protein OD normalized to the OD of TBP) were shown as percentage of 
control (vehicle + TNF- α) (n = 3); **p < 0.01 and *p < 0.05 15d-PGJ2 or MG132 vs. TNF-α.
8
Marcone et al. Proteasome Inhibition and Anti-inflammatory Effects of 15d-PGJ2
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 459
effect of 15d-PgJ2 on ec-conditioned 
Medium-induced Monocyte Migration
Monocytes may be recruited to the vascular endothelium in early 
atherosclerosis through chemotactic factors such as MCP-1, 
MCP-4, and IL-8 that are released in response to activation of 
NF-κB pathway. As shown in Figure 6A, conditioned medium 
from 15d-PGJ2-treated EC that had been exposed to TNF-α 
promoted monocyte chemotaxis and this was suppressed by prior 
incubation of the EC with 15d-PGJ2 in a concentration-dependent 
manner. The proteasomal inhibitor MG132 showed similar effects, 
inhibiting moncoyte chemotaxis by the conditioned medium by 
78 ± 2%. Furthermore, as shown in Figure 6B, both 15d-PGJ2 and 
MG132 significantly decreased EC generation of MCP-1, MCP-4, 
and IL-8 in the conditioned media assayed by ELISA, explaining, 
at least in part, their inhibition of monocyte chemotaxis.
DiscUssiOn
15d-PGJ2 downregulates expression or activity of proinflamma-
tory genes induced by various stimuli (e.g., TNF-α, IL-1b, LPS, 
etc.) in several cell and potentially acts as an endogenous sup-
pressor of inflammation (29, 30). There are a number of possible 
mechanisms for this activity (31). First, 15d-PGJ2 is a ligand for 
peroxisome proliferator-activated receptor gamma (PPAR-γ), 
a member of the nuclear receptor superfamily and a transcrip-
tion factor with pleiotropic effects on adipocyte differentiation, 
FigUre 4 | 15d-PgJ2 inhibits mrna expression of adhesion molecules. (a) VCAM-1, ICAM-1, and E-selectin gene expression was performed in EC treated 
with 15d-PGJ2 (1–10 μM) or MG132 (100 nM) for 18 h, followed by 6 h stimulation with TNF-α (0.2 ng/ml). The treatment of EC with 15d-PGJ2 inhibited gene 
expression of all the adhesion molecules in a dose-dependent fashion. Similar effects were obtained in the MG132-treated samples. Data are expressed as 
mean ± SEM of three independent experiments. (B) The quantification of protein surface expression levels of the adhesion receptors VCAM-1, ICAM-1, and 
E-selectin was performed by flow cytometry analysis on TNF-α-activated EC (6 h, 0.2 ng/ml) pre-incubated with various concentration of 15d-PGJ2 or MG132 
(100 nM). Results show a dose-dependent decrease of protein levels in EC treated with the 15d-PGJ2, as well as MG132. Data are expressed as mean ± SEM of 
three independent experiments. Data shown as percentage of control (vehicle + TNF-α-activated EC); $$$(p < 0.001) vehicle vs. TNF-α; ***p < 0.001, **p < 0.01, and 
*p < 0.05 15d-PGJ2 or M132 vs. TNF-α.
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glucose homeostasis, lipid metabolism, cell growth, and inflam-
mation (29, 32). Second, 15d-PGJ2 also exerts effects by cova-
lently modifying proteins through the reactive α,β-unsaturated 
carbonyl group located in the cyclopentenone ring, a structural 
feature unique to J series prostaglandins (Figure 1A) (9–15). In 
earlier studies, we used biotin-15d-PGJ2 to capture a wide range 
of protein candidates in EC (27). The biotin binds to the carboxyl 
group leaving the cyclopentenone free to interact with free thiol 
groups of proteins. We also showed that 15d-PGJ2 covalently 
modifies proteins in multiple pathways, thereby altering their 
cellular functions; for example, 15d-PGJ2 covalently modified 
nuclear transport proteins, blocked nuclear transport and as a 
consequence altered gene expression (14).
In the present study, we further examined the set of proteins 
previously reported (27) and noted a disproportionate repre-
sentation of proteins from the proteasome, a cellular complex 
that ubiquinates and degrades cellular proteins. The 13 proteins 
identified were solely in the 19S regulatory subunit, demon-
strating extraordinary selectivity. The results were confirmed 
by anti-biotin Western blot for several of the 19S component 
proteins and two 20S protein as control. As we had deliberately 
used a high concentration of 15d-PGJ2 to capture a wide range 
of proteins, we next examined the interaction between biotin-
15d-PGJ2 and purified proteasome proteins. This demonstrated 
that the interaction occurred at nanomolar concentrations of the 
lipid and could be blocked by excess unlabeled 15d-PGJ2. We 
further showed that 15d-PGJ2 inhibited proteasome activity in 
human EC, as did MG132, a known proteasome inhibitor which 
acts by covalently binding to the beta subunits of the proteasome. 
Proteasome inhibitors are either synthetic compounds or natural 
products and have served as tools in the discovery of UPS targets 
and their role in different cellular processes. Several proteasome 
inhibitors are currently used in the treatment of cancer (33, 34). 
The main consequence of proteasome inhibition is a decrease in 
the rate of protein degradation in cells and as a result to a rapid 
accumulation of proteins conjugated to ubiquitin (Figure 2C).
As 15d-PGJ2 acts as an inhibitor of proteasome function, we 
next explored its effects on the activation of the NF-κB pathway 
FigUre 5 | 15d-PgJ2 inhibits human monocyte adhesion to endothelial cells. (a) EC were treated with 15d-PGJ2 or MG132 for 18 h, followed by 6 h 
stimulation with TNF-α (0.2 ng/ml), and a static adhesion assay with fluorescence-labeled THP-1 human monocytes was performed. Adherent monocytes were 
measured in a plate fluorescence reader with 485-nm excitation and 530-nm emission wavelengths. Data were calculated as mean ± SEM of three independent 
experiments. Data are reported as percentage of TNF-α-activated EC; $$$(p < 0.001) vehicle (ethanol) vs. TNF-α; ***p < 0.001 treatments vs. TNF-α. (B) 
Representative fluorescence microscopy photomicrographs of monocyte adhesion to EC are shown.
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in EC in response to TNF-α. The ubiquitous eukaryotic transcrip-
tion factor NF-κB plays a central role in cellular inflammation 
processes (35, 36). NF-κB is sequestered in the cytoplasm within 
an inactive complex comprised of a family of repressors, including 
IκB-α. Phosphorylation of IκB-α triggers its conjugation to ubiq-
uitin and subsequent degradation by the proteasome. As a result, 
NF-κB is liberated from the inhibitory protein and translocates 
to the nucleus where it induces the expression of genes, includ-
ing genes for adhesion molecules, cytokines, and chemokines. 
Inhibition of the proteasome has an additional effect on the NF-κB 
pathway as p50 and p52 are generated from their corresponding 
p105 and p100 precursors by ubiquitin–proteasome-dependent 
degradation. Thus, the processing of IκB-α and p105 is modified 
by proteasome inhibitors such as MG132 (37, 38). Both 15d-PGJ2 
and MG132 inhibited IκB-α degradation and p105 processing 
in response to TNF-α in our experiments. The consequence of 
preventing IκB-α degradation and p105 processing is to stablilise 
NF-κB and prevent its activation and downstream effects. Indeed, 
15d-PGJ2 blocked p65 and p50 nuclear localization in EC in 
response to TNF-α and the expression of inflammatory genes 
including adhesion receptors (VCAM-1, ICAM-1, and E-sel) and 
chemokines (Figure 7).
The incomplete inhibition of proteasomal activity by 15d-
PGJ2 (~44%, p <  0.01) was comparable to that observed with 
MG132 (~58%, p < 0.01). Therefore, these results explain only 
in part the complete inhibition of adhesion molecule expression 
and monocyte recruitment to activated EC. It is possible that 
some of the 15d-PGJ2 anti-inflammatory effects detected in EC 
reflect the modification of other proteins processed by the ubiq-
uitin–proteasome pathway (39), interference with other steps in 
the NF-κB signaling pathway, or by PPAR-γ-dependent mecha-
nisms. Given the reactivity of the cyclopentenone structure, 
15d-PGJ2 may likewise modify other inflammatory pathways, 
independently of proteasome-NF-κB signaling. The proteasome 
system is also responsible for the regulation of transcriptional 
activators such as Keap1-Nrf2, P53, and JAK/STAT, which, in 
turn, modulate inflammatory processes, cell cycle, growth, and 
differentiation (40). Nrf2 plays a crucial role in cellular defense 
(41) and is sequestered by Keap1 in the cytoplasm, which in 
turn undergoes proteasomal degradation under certain stress 
FigUre 6 | 15d-PgJ2 inhibits ec-conditioned-media-induced monocyte migration. (a) (i) THP-1 monocyte migration in response to conditioned medium 
from EC that had been treated with 15d-PGJ2 (1–10 μM) or MG132 (100 nM) and activated with TNF-α was assayed using a 24-well transwell migration plate. 
Migrating cells were stained with DAPI and visualized using a fluorescent microscope. The number of cells in five random 20× fields was counted, and the average 
value was expressed as a percentage of TNF-α-activated EC. (ii) Representative fluorescence microscopy photomicrographs of migrating monocytes are shown. 
Each experiment was carried out independently three times. Data were calculated as mean ± SEM of three independent experiments and reported as percentage of 
TNF-α-activated EC; $$$(p < 0.001) vehicle vs. TNF-α; ***p < 0.001 and **p < 0.01 treatments vs. TNF-α alone. (B) 15d-PGJ2 suppresses chemokine generation. 
Conditioned-media from EC treated with 15d-PGJ2 (1–10 μM) or MG132 (100 nM) and activated with TNF-α was assayed to measure IL-8, MCP-1, and MCP-4 
levels by ELISA. The results are from three independent experiments. Data were calculated as mean ± SEM and reported as percentage of TNF-α-activated EC; 
$$$(p < 0.001), $$(p < 0.01) vehicle vs. TNF-α; **p < 0.01 and *p < 0.05 treatments vs. TNF-α alone.
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conditions, releasing Nrf2 (42). It has also been shown that 
15d-PGJ2 is able to activate the Nrf2 regulatory pathway by 
covalent modification of Keap1 (43). The JAK/STAT cascade is 
an additional inflammatory signaling pathway modified by 15d-
PGJ2 (44). 15d-PGJ2 is also an endogenous agonist of PPAR-γ, a 
nuclear receptor that modulates a variety of cellular processes 
(8, 45). Crystallographic analysis of PPAR-γ revealed that the 
ligand-binding domain (LBD) covalently binds to 15d-PGJ2 
inducing conformational changes in the loop region of LBD (46). 
Finally, 15d-PGJ2 can modulate NF-κB activity by interfering 
directly with members of the NF-κB pathway independently of 
PPAR-γ activation or proteasome inhibition. For example, 15d-
PGJ2 inhibited IKK and the DNA binding of NF-κB in several cell 
types (18), and 15d-PGJ2 directly inhibited and modified IKK-β 
subunit of IKK (17).
The implication of these findings is that 15d-PGJ2 may act 
as an endogenous suppressor of diseases where inflammation is 
a hallmark, for example, in atherosclerosis. The UPS has been 
implicated in the pathogenesis of this disease (25), and 15d-PGJ2 
has been identified in atherosclerotic plaque (47). Furthermore, 
NF-κB is involved in several key processes that influence the 
development of atherosclerotic plaque (48, 49) through the acti-
vation of genes involved in inflammation. Consistent with this, 
modulators of proteasome activity and NF-κB inhibition have 
been demonstrated to be atheroprotective (50–52).
There is a question as to whether cells can produce sufficient 
amounts of free 15d-PGJ2 to have any significant effect. Whereas 
measured concentrations of 15d-PGJ2 in vivo are in the picomolar 
to nanomolar range, the biological effects in in vitro experiments 
are seen at micromolar concentrations. One explanation for the 
discrepancy is that assays of 15d-PGJ2 in  vivo are designed to 
detect the free prostaglandin, while 15d-PGJ2 is largely protein 
bound. Binding to serum proteins (53), as well as sequestration 
by intracellular components (54) and their export from cells as 
water soluble glutathione S-conjugates (55), could explain the 
requirement of micromolar concentrations of 15d-PGJ2 to exert 
biological effects when added exogenously. The experiments here 
showed that exposure of purified 19S particle of the proteasome 
FigUre 7 | The role of proteasome in the nF-κB pathway and the possible effects of inhibition of proteasome activity by 15d-PgJ2.
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to biotin-15d-PGJ2 resulted in a dose-dependent formation of 
15d-PGJ2–protein complexes at nanomolar concentration of 
biotin-15d-PGJ2, demonstrating the interaction between protea-
some and 15d-PGJ2 at levels of prostaglandin that may be achieved 
in vivo. One might also speculate that localized concentrations of 
cyPG in the high nanomolar range may be possible given that 
COX isozymes functionally couple with downstream isozymes 
at discrete locations, such as the nuclear membrane. Finally, as 
15d-PGJ2 exerts its biological effects through irreversible modi-
fication of cellular proteins, 15d-PGJ2 could induce a cumulative 
inactivation of protein targets over time even at very low rates of 
production.
In conclusion, this work was designed to identify novel protein 
targets of 15d-PGJ2 that may be responsible for its anti-inflamma-
tory effects. We found that 15d-PGJ2 covalently modifies com-
ponents of the proteasome thereby inhibiting its functions. The 
results raise the possibility that 15d-PGJ2 may regulate inflamma-
tory processes in EC by modulating proteasome activity. Further 
understanding of the mechanisms involved may identify novel 
targets for the development of anti-inflammatory drugs.
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